Royalty Payment Schedule Sample Clauses

Royalty Payment Schedule. The Licensee will pay to Institute all Earned Royalties payable to Institute quarterly on or before February 28 (for the Calendar Quarter ending December 31), May 31 (for the Calendar Quarter ending March 31), August 31 (for the Calendar Quarter ending June 30) and November 30 (for the Calendar Quarter ending September 30) of each calendar year. Each payment will be for Earned Royalties accrued within the Licensee’s most recently completed Calendar Quarter.

Royalty Payment Schedule. The royalty fees are due and payable according to the following schedule or on such other schedule specified in the Manual:

Royalty Payment Schedule. Within five (5) business days after the end of each Fiscal Quarter during which a Royalty-Bearing Product in the Field of Use is sold by Allergan, its Affiliates or its or their Sublicensees in the Royalty Territory, Allergan shall provide to Spectrum the estimated royalty payment calculation for Spectrum to complete its quarterly accounting close. Within forty-five (45) days after the end of each Fiscal Quarter during which a Royalty-Bearing Product in the Field of Use is sold by Allergan, its Affiliates or its or their Sublicensees in the Royalty Territory, Allergan shall deliver to Spectrum a detailed report, which shall include at least: (a) the net quantity sold, total sales, total to net deducts, and Royalty-Bearing Net Sales of Royalty-Bearing Product in the Field of Use for which royalties are due hereunder that it has sold in the prior Fiscal Quarter; (b) the calculation in U.S. dollars of royalty payments due hereunder with respect to such sales; and (c) the total due hereunder for such Fiscal Quarter, including deduction for any offsets. Simultaneously with the delivery of each such report, Allergan shall pay to Spectrum the amount specified in Section 6.5(c). Notwithstanding the foregoing, to the extent that Royalty-Bearing Net Sales also include Sublicensee Net Sales of Royalty-Bearing Product (including under Sections 6.3 and 6.4), Allergan shall have additional time as reasonably necessary to provide Spectrum with the information relating to such Sublicensee Net Sales of Royalty-Bearing Product in the foregoing report and payment or to determine whether the sales milestones have been met and subsequently make payments therefor.

Royalty Payment Schedule. Guaranteed Minimum Royalties shall be due and payable by Licensee to Licensor in installments as shown above. All other Royalties set forth above, including percentage royalties in excess of minimum royalties, shall be due and payable by Licensee to Licensor in quarterly installments on the twentieth (20th) day after the close of each contract quarter (on a pro rata basis for any period less than twelve (12) months).

Royalty Payment Schedule. Payments under Section 4.1 shall be payable to IntelliPharmaCeutics on a quarterly basis, within thirty (30) days after the end of each calendar quarter; provided, however, at the end of a calendar year, Larasan shall determine the actual amounts owed to IntelliPharmaCeutics under Section 4.1 and any additional amounts owed to IntelliPharmaCeutics for the first three calendar quarters of such calendar year shall be paid with the payment for the last calendar quarter of such calendar year, and provided further in the event that Larasan's payments for such calendar quarters exceed the actual amounts owed for such calendar quarters, Larasan shall have the right to offset such excess payments against the payment for the last calendar quarter of such calendar year. Only one payment will be due on Net Sales of the Licensed Product, even though the manufacture, sale or use of such Licensed Product may be covered by more than one intellectual property right in a country.

Royalty Payment Schedule. Payments due hereunder shall be made by the LICENSEE to LICENSOR on or before the thirtieth (30th) day of April, July, October and January of each calendar year for sale of all Products sold during the immediately preceding calendar quarterly periods ending on the last day of March, June, September and December (each a “Royalty Period”).

Royalty Payment Schedule. Freeze Tag will pay DEVELOPER its earned Royalties on a quarterly basis via check through the US mail (or other certified delivery service) no later than thirty (30) days after the close of the quarter in which royalties have been received by Freeze Tag. Freeze Tag’s fiscal year end is December 31. At DEVELOPER’s request, Freeze Tag will make the Royalty Payment via wire transfer, but the wire transfer fee for this transaction will be subtracted as an expense from the Royalties due to DEVELOPER.

Royalty Payment Schedule. For the first calendar year of Net Sales, the Royalty shall be paid to Gilead in accordance with the schedule set forth in subsection (a) above. Beginning in the second calendar year of Net Sales, Roche’s first three (3) quarterly payments shall be based upon the average royalty rate payable with respect to the previous calendar year. Following the fourth (4th) quarter of each calendar year, Roche shall pay Gilead the Royalty owing for the full year minus the aggregate payments made for the first three quarters or, if the aggregate payments made for the first three quarters exceed the Royalty owing for the full year, Gilead shall refund the difference to Roche.

Royalty Payment Schedule. The payments for 2009 shall be $1 million due by July 10, 2009, and $1 million due by October 1, 2009. The payments for 2010 shall be in quarterly installments of $900,000 due by the first business day of each calendar quarter. The payments for 2011-13 shall be in quarterly installments of $1M due by the first business day of each calendar quarter. The $1.15 million payment for 2014 shall be due by January 2, 2014.

Royalty Payment Schedule. PAR's MARKET SHARE (MS) OF THE ROYALTY AMOUNT TOTAL SUSTAINED RELEASE SOLID (% Of NET SALES) DOSAGE *********** MARKET ------------------------------------------------------ ** % MS > ** % - ------------------------------------------------------ ** % ** %> MS > ** % - ------------------------------------------------------ ** % ** %> MS > ** % - ------------------------------------------------------ * % ** %> MS > ** % - ------------------------------------------------------ * % MS < ** % ------------------------------------------------------ Market share shall be based on the total sales reported for *********** controlled release products which are bioequivalent to ******* ** as reported by IMS at the end of each calendar year. If no patent is granted by the USPTO based on the pending patent applications, the royalty rate will continue for the life of the Agreement.